News for Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences, partnering with HMNC Brain Health, has initiated dosing for the first participant in a Phase 2 clinical trial named TAMARIND. This study is

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder

Spruce Biosciences (SPRB) has captured substantial interest within the biotech sector, as evidenced by a 120% surge in search activity. This notable increase is

Weekly Market Overview The stock market showed resilience but closed lower for the week, with the S&P 500 declining by 0.4%. Key events included U.S.-China

Spruce Biosciences (SPRB) set to resume Nasdaq trading, pending compliance with bid price rules by Aug 2025 via a proposed reverse stock split.

Neurocrine Biosciences Inc (NBIX) exhibits a robust product portfolio with FDA-approved treatments for various neurological and endocrine disorders.Despite inc

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while th...

U.S. stocks traded higher this morning, with the Dow Jones index more than 150 points on Monday. Following the market opening Monday, the Dow traded up 0.47% t...

Operator: Welcome to the Spruce Biosciences Investor Call [Operator Instructions]. Please note, this conference call is being recorded.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to 40,592.77 while the ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up...

Spruce Biosciences (SPRB) has unveiled a fresh corporate strategy focused on the acquisition of tralesinidase alfa, an enzyme replacement therapy aimed at tackl

**media[502868]**

SPRB stock touches 52-week low at $0.37 amid market challenges

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 22.22% and 66.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

SPRB stock touches 52-week low at $0.42 amid market challenges

Oppenheimer cuts Spruce Biosciences shares target, cites updated revenue forecasts